Sympathetic hyperactivity in chronic kidney disease: Pathogenesis, clinical relevance, and treatment

Kidney International

Volumn 65, Issue 5, 2004, Pages 1568-1576

  Neumann, Jutta ^a   Ligtenberg, Gerry ^a   Klein, Inge I ^a   Koomans, Hein A ^a   Blankestijn, Peter J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Angiotensin II; Kidney disease; Renal hypertension; Review; Sympathetic activity

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE; RENIN;

ADRENERGIC SYSTEM; BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; EXTRACELLULAR SPACE; HUMAN; KIDNEY FUNCTION; KIDNEY INJURY; NONHUMAN; PRESSORECEPTOR; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; RISK ASSESSMENT; RISK FACTOR;

EID: 2342453843     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00552.x     Document Type: Conference Paper

References (90)

1. KDOQI Clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 39(Suppl 1):S1-S266, 2002
2. KIM KE, ONESTI G, SCHWARTZ AB, et al: Hemodynamics of hypertension in end stage renal disease. Circulation 46:456-464, 1972
3. VALLBO AB, HAGBARTH KE, TOREBJORK HE, WALLIN BG: Somatosensory, proprioceptive and sympathetic activity in human peripheral nerves. Physiol Rev 59:919-957, 1972
4. GRASSI G, ESLER M: How to assess sympathetic activity in humans. J Hypertens 17:719-734, 1999
5. SUNDLOF G, WALLIN BG: Sympathetic activity and blood pressure. J Physiol 274:621-637, 1977
6. VISSING SF, SCHERRER U, VICTOR RG: Relation between sympathetic outflow and vascular resistance in the calf during perturbations in central venous pressure: Evidence for cardiopulmonary afferent regulation of calf vascular resistance in humans. Circ Res 65:1710-1717, 1989
7. SCHALEKAMP MADH, SCHALEKAMP-KUYKEN MPA, DE MOOR-FRUYTIER M, et al: Interrelationships between blood pressure, renin, renin substrate and blood volume in terminal renal failure. Clin Sci Mol Med 45:417-428, 1973
8. MATSUKAWA T, GOTOH E, MINAMISAWA K, et al: Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. Am J Physiol 30:R690-R696, 1991
9. REID IA: Interactions between ANG II, sympathetic nervous system, and baroreflexes in regulation of blood pressure. Am J Physiol 262:E763-E778, 1992
10. KATHOLI RE, WHITLOW PL, HAGEMAN GR, WOODS WT: Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertens 2:349-359, 1984
11. FABER JE, BRODY MJ: Afferent renal nerve-dependent hypertension following acute renal artery stenosis in the conscious rat. Circ Res 57:676-688, 1985
12. CAMPESE VM, KOGOSOW E, KOSS M: Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 25:878-882, 1995
13. YE S, OZGUR B, CAMPESE VM: Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 51:722-727, 1997
14. YE S, GAMBURD M, MOZAYENI P, et al: A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 11:723-728, 1998
15. CAMPESE VM: Neurogenic factors and hypertension in renal disease. Kidney Int 57(Suppl 75): S2-S6, 2000
16. SANDER M, HANSEN PG, VICTOR RG: Sympathetically mediated hypertension caused by chronic inhibition of nitric oxide. Hypertension 26:691-695, 1995
17. MATSUOKA H, NISHIDA H, NOMURA G, et al: Hypertension induced by nitric oxide synthesis inhibition is renal nerve dependent. Hypertension 23:971-975, 1994
18. YE S, NOSRATI S, CAMPESE V: Nitric oxide (NO) modulates neurogenic control of blood pressure in rats with chronic renal failure. J Clin Invest 99:540-548, 1997
19. CHOWDHARY S, TOWNEND JN: Role of nitric oxide in the regulation of cardiovascular autonomic control. Clin Sci 97:5-17, 1999
20. BREDT DS, HWANG PM, SNYDER SH: Localization of nitric oxide synthase indicating a neuronal role for nitric oxide. Nature 347:768-770, 1990
21. BIGAZZI R, KOGOSOV E, CAMPESE V: Altered norepinephrine turnover in the brain of rats with chronic renal failure. J Am Soc Nephrol 4:1901-1907, 1994
22. YE S, ZHONG H, DUONG VN, CAMPESE VM: Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. Hypertension 39:1101-1106, 2002
23. LEVITAN D, MASSRY SG, ROMOFF M, CAMPESE VM: Plasma catecholamines and autonomic nervous system function in patients with early renal insufficiency and hypertension: effect of clonidine. Nephron 36:24-29, 1984
24. LAEDERACH K, WEIDMANN P: Plasma and urinary catecholamines as related to renal function in man. Kidney Int 31:107-111, 1987
25. CONVERSE RL, JACOBSEN TN, TOTO RD, et al: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327:1912-1918, 1992
26. LIGTENBERG G, BLANKESTIJN PJ, OEY PL, et al: Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340:1321-1328, 1999
27. HAUSBERG M, KOSCH M, HARMELINK P, et al: Sympathetic nerve activity in end-stage renal disease. Circulation 106:1974-1979, 2002
28. CONVERSE RL, JACOBSEN TN, JOST CM, et al: Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysis induced hypotension. J Clin Invest 90:1657-1665, 1992
29. MIYAJIMA E, YAMADA Y, YOSHIDA Y, et al: Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 17:1057-1062, 1991
30. KLEIN IHHT, LIGTENBERG G, NEUMANN J, et al: Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 14:3239-3244, 2003
31. KLEIN IHHT, LIGTENBERG G, OEY PL, et al: Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 12:427-33, 2001
32. EBERT TJ, MORGAN BJ, BARNEY JA, DENAHAN T, et al: Effects of aging on baroreflex regulation of sympathetic activity in humans. Am J Physiol 263:H798-H803, 1992
33. DAVY KP, TANAKA H, ANDROS EA, et al: Influence of age on arterial baroreflex inhibition of sympathetic nerve activity in healthy adult humans. Am J Physiol 275:H1768-H1772, 1998
34. KLEIN LH, LIGTENBERG G, OEY PL, et al: Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 14:425-430, 2003
35. WEVER R, BOER P, HUMERING M, et al: Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 19:1168-1172, 1999
36. KIELSTEIN JT, BOGER RH, BODE-BOGER SM, et al: Marked increase in asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 13:170-176, 2002
37. HANSEN J, JACOBSEN TN, VICTOR RG: Is nitric oxide involved in the tonic inhibition of central sympathetic outflow in humans? Hypertension 24:439-444, 1994
38. LEPORI M, SARTORI C, TRUEB L, et al: Haemodynamic and sympathetic effects of inhibition of nitric oxide synthase by systemic infusion of N(G)-monomethyl-L-arginine into humans are dose dependent. J Hypertens 16:519-523, 1998
39. ZOCCALI C, BODE-BOGER SM, MALLMAC F, et al: Plasma concentrations of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 358:2113-2117, 2001
40. ZOCCALI C, MALLAMACI F, MAAS R, et al: Left ventricular hypertrophy, cardiac remodelling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62:339-345, 2002
41. MALLAMACI F, TRIPEPI G, RENKE M, et al: An analysis of the relationship between norepinephrine and asymmetric dimethyl arginine (ADMA) in patients with end stage renal disease. J Am Soc Nephrol 15:435-441, 2004
42. FAGUGLI RM, REBOLDI G, QUINTALIANI G, et al: Short daily hemodialysis blood pressure control and left ventricular mass reduction in hypertensive hemodialyis patients. Am J Kidney Dis 38:371-376, 2001
43. NESRALLAH G, SURI R, MOIST L, et al: Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am J Kidney Dis 42(Suppl 1):S13-S17, 2003
44. CHAN C, FLORAS JS, MILLER JA, et al: Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 61:2235-2239, 2002
45. VOS PF, ZILCH O, KOOISTRA MP: Clinical outcome of daily dialysis. Am J Kidney Dis 37(Suppl 2):S99-S102, 2001
46. KELSTEIN JT, BODE-BOGER SM, FROHLICH JC, et al: Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int 59(Suppl 78): S9-S13, 2001
47. SCHRODER M, RIEDEL E, BECK W, et al: Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes. Kidney Int 59(Suppl 78):S19-S24, 2001
48. HANLY PJ, PIERRATOS A: Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 344:102-107, 2001
49. SCHOHN D, WEIDMANN P, JAHN H, BERETTA-PICCOLI C: Norepinephrine related mechanisms in hypertension accompanying renal failure. Kidney Int 28:814-822, 1985
50. KELM M, SCHAFER S, MINGER S, et al: Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens 14:1357-1364, 1996
51. GREENWOOD JP, SCOTT EM, STOKER JB, MARY DA: Hypertensive left ventricular hypertrophy: Relation to peripheral sympathetic drive. J Am Coll Cardiol 38:1711-1717, 2001
52. SCHLAICH MP, KAYE DM, LAMBERT E, et al: Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108:560-565, 2003
53. ZOCCALI C, MALLAMACI F, TRIPEPI G, et al: Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 40:41-46, 2002
54. LEVIN A, DJURDJEV O, BARNETT B, et al: Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter. Am J Kidney Dis 38:1398-1407, 2001
55. SILVERBERG JS, BARRE PE, PRICHARD SS, SNIDERMAN AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36:286-290, 1989
56. FOLEY RN, PARFREY PS, HARNETT JD, et al: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 5:2024-2013, 1995
57. ZOCCALI C, BENEDETTO FA, MALLAMACI LS, et al: Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12:2768-2774, 2001
58. JULIUS S: Sympathetic hyperactivity and coronary risk in hypertension. Hypertension 21:886-893, 1993
59. MANCIA G, GRASSI G, GIANNATTASIO C, SERAVALLE G: Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Circulation 34:724-728, 1999
60. ZOCCALI C, MALLAMACI F, PARLONGO S, et al: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105:1354-1359, 2002
61. AMANN K, RUMP LC, SIMONAVICIENE A, et al: Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 11:1469-1478, 2000
62. AMANN K, KOCH A, HOFSTETTER J, et al: Glomerulosclerosis and progression: effect of subantihypertensive doses of alfa and beta blockers. Kidney Int 60:1309-1323, 2001
63. STROJEK K, GRZESZCZAK W, GORSKA J, et al: Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: Novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 12:602-605, 2001
64. SAKATA K, SHIROTANI M, YOSHIDA H, KURATA C: Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension. J Am Coll Cardiol 32:438-443, 1998
65. SAKATA K, YOSHIDA H, OBAYASHI K, et al: Effects of losartan and its combination with quinapril on the cardiac sympathetic nervous system and neurohumoral status in essential hypertension. J Hypertens 20:103-110, 2002
66. KASAMA S, TOYAMA T, KUMAKURA H, et al: Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 19:574-581, 2003
67. AZEVEDO ER, KUBO T, MAK S, et al: Nonselective versus selective beta-adrenergic recepror blockade in congestive heart failure. Circulation 104:2194-2199, 2001
68. SCHMIEDER RE, MARTUS P, KLINGBEIL A: Reversal of left ventricular hypertrophy en essential hypertension: A meta-analysis of randomized double-blind studies. JAMA 275:1507-1513, 1996
69. LONDON GM, PANNIER B, GUERIN AP, et al: Cardiac hypertrophy, aortic compliance, peripheral resistance and wave reflection in end stage renal disease: Comparative effects of ACE inhibition and calcium channel blockade. Circulation 90:2786-2796, 1994
70. CANNELLA G, PAOLETTI E, DELFINO R, et al: Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on log-term antihypertensive therapy. Kidney Int 44:881-886, 1993
71. CANNELLA G, PAOLETTI E, DELFINO R, et al: Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 30:659-664, 1997
72. DYADYK AI, BAGRIY AE, LEBEB IA, et al: ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. Nephrol Dial Transplant 12:945-951, 1997
73. FRANCIS GS, COHN JN, JOHNSON G, et al, for the V-HeFT VA Cooperative Studies Group: Plasma norepinephrine, plasma renin activity, and congestive heart failure: Relations to survival and the effects of therapy in V-HeFT II. Circulation 87:VI-40-VI-48, 1993
74. EFRATI S, ZAIDENSTEIN R, DISHY V, et al: ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 40:1023-1029, 2002
75. MANN JF, GERSTEIN HC, POGUE J, et al: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134:629-636, 2001
76. CICE G, FERRARA L, D'NDREA A, et al: Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy. J Am Soc Cardiol 41:1438-1444, 2003
77. FOLEY RN, HERZOG CA, COLLINS AJ: Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 62:1784-1790, 2002
78. SCHWENGER V, RITZ E: Audit of antihypertensive treatment in patients with renal failure. Nephrol Dial Transplant 13:3091-3095, 1998
79. VONEND O, MARSALEK P, RUSS H, et al: Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 21:1709-1717, 2003
80. TONELLI M, BOHM C, PANDEYA S, et al: Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 37:484-489, 2001
81. SARAN R, DYKSTRA DM, WOLFE RA, et al: Association between vascular access failure and the use of specific drugs: The Dialysis Outcomes and Practice Patterns study (DOPPS). Am J Kidney Dis 40:1255-1263, 2002
82. WRIGTS RS, REEDER GS, HERZOG CA, et al: Acute myocardial infarction and renal dysfuction: a high risk combination. Ann Intern Med 137:563-570, 2002
83. GUIDELINES COMMITTEE: 2003 European Society of Hypertension - European Society of Cardiology Guidelines for the Management of Arterial Hypertension. J Hypertens 21:1011-1053, 2003
84. CHOBANIAN AV, BAKRIS GL, BLACK HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289:2560-2572, 2003
85. ESLER M: Differentiation in the effects of angiotensin II receptor blocker class. J Hypertens 20(Suppl 5):S13-S19, 2002
86. KALINOWSKI L, DOBRUCKI LW, SZCZEPANSKA-KONKEL M, et al: Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: A novel mechanism for antihypertensive action. Circulation 107:2747-2752, 2003
87. PLIQUETT RU, CORNISH KG, PEULER JD, ZUCKER IH: Simvastatine normalizes neural control in experimental heart failure. Circulation 107:2493-2498, 2003
88. WENTING GJ, BLANKESTIJN PJ, POLDERMANS D, et al: Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril. Am J Cardiol 59:92D-97D, 1987
89. DIKOW R, ADAMCZAK M, HENRIQUEZ DE, RITZ E: Strategies to decrease cardiovascular mortality in patients with end-stage renal disease. Kidney Int 61(Suppl 61):S5-S10, 2002
90. ZOCCALI C, MALLAMACI F, TRIPEPI G: Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int 63(Suppl 85):S105-S110, 2003